Edition:
United States

Pluristem Therapeutics Inc (PSTI.A)

PSTI.A on American Stock Exchange

1.62USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$1.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
137
52-wk High
$2.00
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia
Tuesday, 9 Jan 2018 07:00am EST 

Jan 9 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​.FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY.  Full Article

Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Pluristem Therapeutics Inc :Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD.  Full Article

PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE
Monday, 30 Oct 2017 02:45pm EDT 

Oct 30 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE.PLURISTEM THERAPEUTICS INC - ‍PRICING OF PUBLIC OFFERING OF 9 MILLION SHARES ON TEL AVIV STOCK EXCHANGE AT PRICE OF $1.67 (NIS 5.90) PER SHARE​.  Full Article

Pluristem extends trial for treatment of insufficient hematopoietic recovery
Thursday, 26 Oct 2017 07:00am EDT 

Oct 26 (Reuters) - Pluristem Therapeutics Inc :Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel.Pluristem therapeutics inc - ‍Israeli clinical sites will join an ongoing u.s. Phase I trial​.  Full Article

FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy
Thursday, 19 Oct 2017 07:30am EDT 

Oct 19 (Reuters) - Pluristem Therapeutics Inc :FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome.  Full Article

Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Pluristem Therapeutics Inc ::Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture.Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture.Pluristem- ‍ proposed Phase III trial will be double-blind, randomized, placebo-controlled trial with about 180 patients enrolled in U.S. and Europe​.Pluristem Therapeutics Inc - Pluristem plans to use results of trial of PLX-PAD to achieve marketing approval in both U.S. And Europe.Pluristem Therapeutics Inc - ‍plans to submit investigational new drug (IND) and clinical trial application (CTA) for trial in coming months​.  Full Article

U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Pluristem Therapeutics Inc :U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli).Pluristem Therapeutics Inc - Pluristem's ongoing phase III cli trial has been selected for accelerated approval pathways in both U.S. and Europe.  Full Article

U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project
Wednesday, 16 Aug 2017 07:30am EDT 

Aug 16 (Reuters) - Pluristem Therapeutics Inc :U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure.Pluristem Therapeutics Inc - DOD studies seek to test effectiveness of PLX-R18 as a novel medical countermeasure for acute radiation syndrome.Pluristem Therapeutics Inc - DOD studies will be conducted in parallel with ongoing ARS project with nih.  Full Article

Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Pluristem Therapeutics Inc :Pluristem advances its multinational phase III critical limb ischemia study, targeting initiation at 40 active sites by the end of 2017.‍Austria's regulatory health agency clears CLI study and joins U.S., U.K., and Germany in conducting 250-patient phase III trial​.‍Phase III CLI trial has received an $8 million grant from European Union's horizon 2020 program​.  Full Article

Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing
Friday, 7 Jul 2017 08:40am EDT 

July 7 (Reuters) - Pluristem Therapeutics Inc :Pluristem Therapeutics Inc - On July 7, 2017, co entered into an at market issuance sales agreement - SEC Filing.Pluristem Therapeutics Inc - Pluristem may issue and sell shares of common stock having aggregate offering price of up to $80 million from time to time.  Full Article

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION